Sigma has retired its syndicated debt facility of $325 million and fully repaid the ANZ off balance sheet debtors securitisation facility of $358 million.
Sigma Pharmaceuticals Limited announced that it had revised guidance for its underlying FY2011 EBIT to a range of between $120 million to $130 million. Over the latter part of the fiscal year, trading conditions have been solid and management expect the underlying FY2011 EBIT to be at the higher end of the range announced in November
The Company?s net cash position after all debt repayments in early February 2011 was approximately $210 million....
Pity about the further goodwill write downs of 20-50 million....
Otherwise i'm really looking forward to the 28th of March :)
What do you guys think?
SIP Price at posting:
44.0¢ Sentiment: None Disclosure: Held
